HCAT - Health Catalyst, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.55
-0.56 (-1.86%)
As of 11:10AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close30.11
Open29.40
Bid29.39 x 1100
Ask29.63 x 900
Day's Range29.28 - 29.98
52 Week Range26.00 - 49.85
Volume79,407
Avg. Volume272,635
Market Cap1.08B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-28.31
Earnings DateFeb 26, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est49.00
  • J.P. Morgan: 2 “Strong Buy” Healthcare Stocks With Over 50% Upside
    TipRanks

    J.P. Morgan: 2 “Strong Buy” Healthcare Stocks With Over 50% Upside

    Digitization of the world we live in has disrupted the healthcare industry, giving rise to the healthcare information technology (IT) segment of the market. The emergence of this space and the technology it offers has transformed the way healthcare providers and organizations care for patients. Not to mention efficiency has improved dramatically. Demand for these digital solutions isn’t expected to slow anytime soon, with Grand View Research predicting that the digital healthcare market will expand at a CAGR of 27%, reaching $509.2 billion by 2025.Bearing this in mind, investing firm J.P. Morgan took a look at several healthcare IT names ahead of their upcoming fourth quarter earnings releases.“Sentiment on the group has been largely favorable, with the group up 12% since Q3 earnings in November vs the remaining Healthcare Technology & Distribution group up 14% and the SPX 8%-plus,” analyst Anne Samuel commented.In the report, the firm highlights two tickers in particular that it believes can not only deliver solid prints, but also reward investors through 2020 and beyond. After using TipRanks’ Stock Screener tool, we found out each boasts a “Strong Buy” consensus rating from the Street, and has a substantial upside potential from the current share price. We’re talking more than 50% here.Health Catalyst Inc. (HCAT)With its cloud-based data platform, Health Catalyst offers data and analytics solutions to healthcare organizations. As the company gears up for its February 27 earnings release, J.P. Morgan has high hopes.The investment banking firm's analyst, Anne Samuel, notes that she will be focused on how many new Data Operating System (DOS) clients were added during the year as well as dollar-based retention. Additionally, Samuel highlights the fact that the company thinks the Medicity conversion opportunity is approaching an inflection point in 2020 given that this past summer, cross-sell conversations kicked off.Based on Samuel’s estimates, the analyst expects net new customers for 2019 to land at 14, which would reflect 28% year-over-year customer growth. In terms of 2020 guidance, she is forecasting 18 net new DOS subscription customers and 7% same-store growth, amounting to 25% DOS subscription revenue growth. However, thanks to Medicity drag, the total revenue gain is expected to come in at 22%. As a result, this brings the 2020 revenue prediction to $186 million, which falls in line with the consensus.While Samuel does point out that HCAT operates in a highly competitive environment and that there could be an expense shift of $200,00 from Q3 into Q4, her bullish thesis remains very much intact. “We see significant white space in an $8 billion TAM, with over 20% revenue growth driven by mid-teens annual customer wins. We estimate the company reaches EBTIDA profitability in the next four years as a maturing customer base drives incremental leverage. The model is predictable with over 90% recurring revenue, 107% net dollar-based retention, and a sticky customer base, never having lost an all-access customer,” the analyst explained.Taking all of this into consideration, Samuel maintained both her Overweight call and $50 price target. Should this target be met, shares could be in for a twelve-month gain of 66%. (To watch Samuel’s track record, click here)Overall, it has been relatively quiet when it comes to other analyst activity. In the last three months, only 3 analysts have issued ratings. However, as they were all Buys, the word on the Street is that HCAT is a Strong Buy. Based on the $48.33 average price target, shares could climb 60% higher in the next twelve months. (See Health Catalyst stock analysis on TipRanks)Livongo Health Inc. (LVGO)Moving on to the firm’s next pick, we come across Livongo Health. For patients battling chronic health conditions, its digital health platform makes it easy to access personalized digital guidance and health coaching through a smart connected device. While the healthcare name has experienced significant volatility, the firm remains optimistic.Ahead of its Q4 earnings release on March 2, Samuel, who also covers this stock, wrote that LVGO already “blessed Street numbers on its Q3 call for $276 million equating to 63% year-over-year growth.” She added, “Looking at the economic value added (EVA) that they reported in Q3, a 40% conversion rate on $208 million year-to-date EVA would equate to a 70% revenue growth run rate on our math.”When the results are announced, Samuel anticipates that the Street will be paying close attention to 2020 guidance and the sustainability of rapid growth, noting that management stated 2020 will be an “investment year”. On top of this, the analyst is hoping for an update on enrollment, pipeline for new growth and any changes in the competitive landscape.In terms of the fourth quarter figures, Samuel is calling for revenue of $49.4 million and an EBITDA loss of $5.5 million, both of which would land within the guided range. For 2020, the analyst expects the company to guide for $281 million in revenue, a 66% increase if achieved, gross profit margins of 72% and a fiscal 2020 EBITDA loss of $25 million.Despite the EBITDA figure being in the red, Samuel believes LVGO will be able to reach operating income profitability in 2021. Additionally, the analyst argued, “The company is minimally penetrated in a vast and growing chronic disease market, as more than half of the U.S. population has one or more chronic conditions and an additional 4,000 Americans are diagnosed with diabetes each day. LVGO’s rapid growth profile is attractive, and unique in Healthcare IT with our model calling for an 85% revenue CAGR over the next 3 years as the company increases its member base.”In line with her optimistic take, Samuel kept an Overweight rating and price target of $43 on the stock. This target conveys her confidence in LVGO’s ability to climb 55% higher in the next twelve months.What does the rest of the Street think about LVGO? As it turns out, other analysts are on the same page. With 100% Street support, the message is clear: the stock is a Strong Buy. Not to mention the $45.67 average price target implies 64% upside potential. (See Livongo stock analysis on TipRanks)

  • GlobeNewswire

    Health Catalyst to Participate in Upcoming Investor Conference

    SALT LAKE CITY, Feb. 24, 2020 -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

  • GlobeNewswire

    Health Catalyst Announces Agreement to Acquire Able Health, a Leading SaaS Provider of Quality and Regulatory Measurement Tracking and Reporting

    Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that it has entered into a definitive agreement to acquire Able Health, Inc. (“Able Health”), a San Francisco-based company that is a leading SaaS provider of quality and regulatory measurement tracking and reporting to healthcare providers and risk-bearing entities. The Able Health SaaS application will strengthen Health Catalyst’s existing Quality and Regulatory Measures capabilities.

  • GlobeNewswire

    Health Catalyst to Announce Fourth Quarter and Full Year 2019 Operating Results and Host Conference Call on Thursday, February 27, 2020

    SALT LAKE CITY, Feb. 14, 2020 -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

  • PR Newswire

    Health Catalyst Joins the Partnership on AI

    Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced its membership in the Partnership on AI (PAI) as its first ever healthcare member.

  • Is Health Catalyst, Inc. (NASDAQ:HCAT) Worth US$37.0 Based On Its Intrinsic Value?
    Simply Wall St.

    Is Health Catalyst, Inc. (NASDAQ:HCAT) Worth US$37.0 Based On Its Intrinsic Value?

    Does the January share price for Health Catalyst, Inc. (NASDAQ:HCAT) reflect what it's really worth? Today, we will...

  • PR Newswire

    WakeMed Health & Hospitals Selects Health Catalyst to Transform Healthcare Delivery through Centralized Data and Analytics

    Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that WakeMed Health & Hospitals (WakeMed) will implement Health Catalyst's Data Operating System (DOS™) and Rapid Response Analytics (RRA) solution which will assist WakeMed in providing efficient, quality care across the Raleigh, N.C.-based health system.

  • GlobeNewswire

    Health Catalyst to Participate in Upcoming J.P. Morgan Healthcare Conference

    SALT LAKE CITY, Dec. 30, 2019 -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

  • Hedge Funds Welcomed Health Catalyst, Inc (HCAT) With Open Arms
    Insider Monkey

    Hedge Funds Welcomed Health Catalyst, Inc (HCAT) With Open Arms

    Russell 2000 ETF (IWM) lagged the larger S&P 500 ETF (SPY) by more than 10 percentage points since the end of the third quarter of 2018 as investors first worried over the possible ramifications of rising interest rates and the escalation of the trade war with China. The hedge funds and institutional investors we track […]

  • Can The Uptrend Continue for Health Catalyst?
    Zacks

    Can The Uptrend Continue for Health Catalyst?

    As of late, it has definitely been a great time to be an investor Health Catalyst.

  • PR Newswire

    Leading Healthcare Organizations Choose Health Catalyst to Accelerate Cost-Management Transformation and Savings

    Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to health care organizations, today announced that INTEGRIS Health and Woman's Hospital join a growing group of forward-thinking health systems selecting Health Catalyst's activity-based costing and cost insights technology, the CORUS™ suite, to drive transparency on the cost of patient care and surface opportunities to improve outcomes.

  • GlobeNewswire

    Health Catalyst to Participate in Upcoming Investor Conferences

    SALT LAKE CITY, Nov. 20, 2019 -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

  • PR Newswire

    Steward Health Care Chooses Health Catalyst for Data-Driven Patient Care Expansion

    Data Operating System and Rapid Response Analytics provide a data management system foundation to accelerate data source integration and actionable insights for improved outcomes and lower costs SALT LAKE ...

  • PR Newswire

    Industry Veterans Form Transformation Capital to Focus on High-Growth Digital Health Companies

    Former Managing Partners of Leerink Transformation Partners form new management company to manage existing $313 million fund and future funds. BOSTON , Nov. 18, 2019 /PRNewswire/ -- The Managing Partners ...

  • GlobeNewswire

    Health Catalyst Reports Third Quarter 2019 Results

    SALT LAKE CITY, Nov. 12, 2019 -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today.

  • GlobeNewswire

    Experienced Technology Executives Julie Larson-Green and S. Dawn Smith appointed to Health Catalyst Board of Directors

    The board of directors (the “Board”) of Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, appointed Julie Larson-Green and S. Dawn Smith to its Board, effective January 1, 2020. “We are honored to add these experienced leaders to our board to enhance Health Catalyst’s ability to continue to achieve our mission to be the catalyst for massive, measurable, data-informed healthcare improvement,” said Dan Burton, CEO of Health Catalyst.

  • GlobeNewswire

    Health Catalyst to Announce Third Quarter 2019 Operating Results and Host Conference Call on Tuesday, November 12, 2019

    SALT LAKE CITY, Oct. 22, 2019 -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare.

  • Interested in Health Catalyst? Be a Patient Buyer
    TheStreet.com

    Interested in Health Catalyst? Be a Patient Buyer

    Health Catalyst is a new issue. What do they do? HCAT "is a mission-driven data warehousing, analytics and outcomes-improvement company that helps healthcare organizations". One caller during Jim Cramer's Mad Money Lightning Round inquired about it - "Wait for it to come down, that is a great company," said Cramer.

  • GlobeNewswire

    Health Catalyst Reports Second Quarter 2019 Results

    SALT LAKE CITY, Aug. 22, 2019 -- Health Catalyst, Inc. (Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today.

  • PR Newswire

    Health Catalyst Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

    SALT LAKE CITY , July 30 , 2019 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, ...

  • PR Newswire

    Health Catalyst Announces Pricing of Initial Public Offering

    SALT LAKE CITY , July 25, 2019 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, ...